{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:56:38Z","timestamp":1791338198758,"version":"4.3.1"},"publisher-location":"Cham","reference-count":130,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319185170","type":"print"},{"value":"9783319185187","type":"electronic"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/82_2015_440","type":"book-chapter","created":{"date-parts":[[2015,3,29]],"date-time":"2015-03-29T01:59:10Z","timestamp":1427594350000},"page":"1-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["HIV Therapy\u2014The State of ART"],"prefix":"10.1007","author":[{"given":"David","family":"Looney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,29]]},"reference":[{"key":"440_CR1","doi-asserted-by":"crossref","unstructured":"Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408):482\u2013485 (PMCID: PMC3704185)","DOI":"10.1038\/nature11286"},{"key":"440_CR2","doi-asserted-by":"publisher","unstructured":"Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM (2014) HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis 210(5):728\u2013735. doi:10.1093\/infdis\/jiu155 (Epub 2014 Mar 11. PMC4148603)","DOI":"10.1093\/infdis\/jiu155"},{"key":"440_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/sti.79.4.340","volume":"79","author":"A Arenas-Pinto","year":"2003","unstructured":"Arenas-Pinto A, Grant AD, Edwards S, Weller IVD (2003) Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 79:340\u2013344","journal-title":"Sex Transm Infect"},{"issue":"8740","key":"440_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/0140-6736(91)91294-5","volume":"337","author":"E Arnaudo","year":"1991","unstructured":"Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA (1991) Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337(8740):508\u2013510","journal-title":"Lancet"},{"issue":"5","key":"440_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P et al (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367(5):399\u2013410","journal-title":"N Engl J Med"},{"key":"440_CR6","doi-asserted-by":"crossref","unstructured":"Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC (2000) A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14(9):F83\u2013F93 (The CPCRA 046 study team for the terry beirn community programs for clinical research on AIDS)","DOI":"10.1097\/00002030-200006160-00001"},{"key":"440_CR7","doi-asserted-by":"crossref","unstructured":"Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC (2009) Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52:203","DOI":"10.1097\/QAI.0b013e3181b033ab"},{"key":"440_CR8","doi-asserted-by":"crossref","unstructured":"Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V (2003) First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials 4(1):11\u201319","DOI":"10.1310\/HF1J-3P6K-1K9H-AGPY"},{"issue":"3","key":"440_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00126334-200107010-00004","volume":"27","author":"JR Bogner","year":"2001","unstructured":"Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, Goebel FD (2001) Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27(3):237\u2013244","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"440_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/QAD.0b013e32835f6b0c","volume":"27","author":"AH Borges","year":"2013","unstructured":"Borges AH, Silverberg MJ, Wentworth D et al (2013) Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 27(9):1433\u20131441","journal-title":"AIDS"},{"key":"440_CR11","doi-asserted-by":"crossref","unstructured":"Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B et al (2001) Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis 33:1931\u20131937","DOI":"10.1086\/324353"},{"issue":"8","key":"440_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1056\/NEJMoa022048","volume":"348","author":"SA Bozzette","year":"2003","unstructured":"Bozzette SA, Ake CF, Tam HK et al (2003) Cardiovascular and cerebrovascular events in patients treatedfor human immunodeficiency virus infection. N Engl J Med 348(8):702","journal-title":"N Engl J Med"},{"issue":"8","key":"440_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1086\/319745","volume":"32","author":"P Brown","year":"2001","unstructured":"Brown P, Crane L (2001) Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin Infect Dis 32(8):1221\u20131226","journal-title":"Clin Infect Dis"},{"key":"440_CR14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","volume":"50","author":"M Caron","year":"2001","unstructured":"Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50:1378\u20131388","journal-title":"Diabetes"},{"key":"440_CR15","doi-asserted-by":"crossref","unstructured":"Carr A (2000) HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 30(Suppl 2):S135\u2013S142","DOI":"10.1086\/313854"},{"key":"440_CR16","first-page":"351","volume":"1998","author":"A Carr","year":"1881","unstructured":"Carr A, Samaras K, Chisolm DJ, Cooper DA (1881) Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998:351","journal-title":"Lancet"},{"key":"440_CR17","doi-asserted-by":"publisher","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy (LD) hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51","journal-title":"AIDS"},{"key":"440_CR18","doi-asserted-by":"publisher","unstructured":"Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM (2014) Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 210(3):354\u2013362. doi:10.1093\/infdis\/jiu051 (Epub 2014 Jan 19. PubMed PMID: 24446523; PubMed Central) (VIKING-3 study group)","DOI":"10.1093\/infdis\/jiu051"},{"key":"440_CR19","unstructured":"CDC (2011) Vital signs: HIV diagnosis, care, and treatment among persons living with HIV\u2014United States. MMWR 63(47):1113\u20131117"},{"issue":"4","key":"440_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/108729103321619773","volume":"17","author":"M Chesney","year":"2003","unstructured":"Chesney M (2003) Adherence to HAART regimens. AIDS Patient Care STDS 17(4):169\u2013177","journal-title":"AIDS Patient Care STDS"},{"issue":"9883","key":"440_CR21","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P et al (2013) Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381(9883):2083\u20132090","journal-title":"Lancet"},{"key":"440_CR22","doi-asserted-by":"crossref","unstructured":"Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D\u2019Aquila RT (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361(6413):650\u2013654 (Erratum in: Nature. 1993 Aug 19; 364(6439):679. PubMed PMID: 7679778)","DOI":"10.1038\/361650a0"},{"key":"440_CR23","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/nm1295-1284","volume":"1","author":"T-W Chun","year":"1995","unstructured":"Chun T-W, Finzi D, Margolick J, Chadwich K, Schwartz D, Siliciano RF (1995) Fate of HIV-1-infected T cells in vivo: rates of transition to stable latency. Nat Med 1:1284\u20131290","journal-title":"Nat Med"},{"issue":"3","key":"440_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00002030-200202150-00008","volume":"16","author":"A Cingolani","year":"2002","unstructured":"Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A (2002) Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16(3):369\u2013379","journal-title":"AIDS"},{"issue":"1","key":"440_CR25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/135965350000500102","volume":"5","author":"P Clevenbergh","year":"2000","unstructured":"Clevenbergh P, Durant J, Halfon P, Giudice P, Mondain. V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P (2000) Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The viradapt study: week 48 follow-up. Antivir Ther 5(1):65\u201370","journal-title":"Antivir Ther"},{"key":"440_CR26","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1086\/323783","volume":"33","author":"ME Coghlan","year":"2001","unstructured":"Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA (2001) Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 33:1914\u20131921","journal-title":"Clin Infect Dis"},{"key":"440_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.7326\/0003-4819-119-8-199310150-00003","volume":"119","author":"AC Collier","year":"1993","unstructured":"Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG et al (1993) Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 119:786\u2013793","journal-title":"Ann Intern Med"},{"key":"440_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM199307293290501","volume":"329","author":"DA Cooper","year":"1993","unstructured":"Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, Gonzalez-Lahoz J et al (1993) Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med 329:297\u2013303","journal-title":"N Engl J Med"},{"issue":"26","key":"440_CR29","doi-asserted-by":"publisher","first-page":"23213","DOI":"10.1074\/jbc.R100027200","volume":"276","author":"R Craigie","year":"2001","unstructured":"Craigie R (2001) HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 276(26):23213\u201323216","journal-title":"J Biol Chem"},{"issue":"3","key":"440_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3851\/IMP1959","volume":"17","author":"H Crauwels","year":"2012","unstructured":"Crauwels H, Vingerhoets J, Ryan R et al (2012) Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther 17(3):439\u2013446","journal-title":"Antivir Ther"},{"issue":"9","key":"440_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1086\/496892","volume":"192","author":"SG Deeks","year":"2005","unstructured":"Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN (2005) Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 192(9):1537\u20131544 Epub 2005 Sep 20","journal-title":"J Infect Dis"},{"issue":"50 Suppl 3","key":"440_CR32","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1086\/651480","volume":"15","author":"V DeGruttola","year":"2010","unstructured":"DeGruttola V, Smith DM, Little SJ, Miller V (2010) Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis 15(50 Suppl 3):S102\u2013S107. doi:10.1086\/651480 (Review. PubMed PMID: 20397937; PubMed Central PMCID: PMC2913596)","journal-title":"Clin Infect Dis"},{"key":"440_CR33","unstructured":"Department of Health and Human Services (2014) DHHS adult and adolescent guidelines\u2014panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Section accessed 13 Nov 2014"},{"key":"440_CR34","doi-asserted-by":"crossref","unstructured":"Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49(11):4721\u20134732 (PMCID: PMC1280117)","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"440_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1172\/JCI200316261","volume":"111","author":"J Dressman","year":"2003","unstructured":"Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, Meade D, Li XA, Zhu W, Uittenbogaard A, Wilson ME, Smart EJ (2003) HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111:389\u2013397","journal-title":"J Clin Invest"},{"issue":"9","key":"440_CR36","doi-asserted-by":"publisher","first-page":"e44454","DOI":"10.1371\/journal.pone.0044454","volume":"7","author":"DA Duprez","year":"2012","unstructured":"Duprez DA, Neuhaus J, Kuller LH et al (2012) Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 7(9):e44454","journal-title":"PLoS One"},{"issue":"6439","key":"440_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/364679b0","volume":"364","author":"EA Emini","year":"1993","unstructured":"Emini EA, Graham DJ, Gotlib L, Condra JH, Byrnes VW, Schleif WA (1993) HIV and multidrug resistance. Nature 364(6439):679","journal-title":"Nature"},{"issue":"9300","key":"440_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","volume":"359","author":"J Fellay","year":"2002","unstructured":"Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV (2002) Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359(9300):30\u2013306","journal-title":"Lancet"},{"key":"440_CR39","doi-asserted-by":"publisher","first-page":"23832","DOI":"10.1074\/jbc.M101156200","volume":"276","author":"JY Feng","year":"2001","unstructured":"Feng JY, Johnson AA, Johnson KA, Anderson KS (2001) Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 276:23832\u201323837","journal-title":"J Biol Chem"},{"key":"440_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJM198707233170401","volume":"317","author":"MA Fischl","year":"1987","unstructured":"Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT et al (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 317:185\u2013191","journal-title":"N Engl J Med"},{"key":"440_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0009-9236(98)90182-5","volume":"64","author":"CV Fletcher","year":"1998","unstructured":"Fletcher CV, Acosta EP, Henry K et al (1998) Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 64:331\u2013338","journal-title":"Clin Pharmacol Ther"},{"key":"440_CR42","doi-asserted-by":"crossref","unstructured":"Friiis-M\u01ffller N,Weber R, D\u2019Armininio Monforte A et al (2003) Exposure to HAART is associated with an increased risk of myocardial infarction: the D:A:D study. In: Presented at: 10th conference on retroviruses and opportunistic, Abstract No. 130, Boston, Mass, 10\u201314 Feb 2003","DOI":"10.2165\/00128413-200313780-00026"},{"key":"440_CR43","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","volume":"85","author":"PA Furman","year":"1986","unstructured":"Furman PA, Fyfe JA, St.Clair MH, Weinhold K, Rideout JL, Freeman GA et al (1986) Phosphorylation of 3\u2032-azido-3\u2032-deoxythymidine and selective interaction of the 5\u2032-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci 85:8333\u20138337","journal-title":"Proc Natl Acad Sci"},{"key":"440_CR44","doi-asserted-by":"crossref","unstructured":"Garcia-Diaz A, McCormick A, Booth C, Gonzalez D, Sayada C, Haque T, Johnson M, Webster D (2014) Analysis of transmitted HIV-1 drug resistance using 454 ultra-deep-sequencing and the DeepChek(\u00ae)-HIV system. J Int AIDS Soc 17(4 Suppl 3):19752 (PMCID: PMC4225408)","DOI":"10.7448\/IAS.17.4.19752"},{"issue":"4","key":"440_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1089\/apc.2006.0070","volume":"21","author":"BL Gilliam","year":"2007","unstructured":"Gilliam BL, Sajadi MM, Amoroso A, Davis CE, Cleghorn FR, Redfield RR (2007) Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. AIDS Patient Care STDS 21(4):240\u2013246","journal-title":"AIDS Patient Care STDS"},{"key":"440_CR47","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.7326\/0003-4819-124-12-199606150-00002","volume":"124","author":"NM Graham","year":"1996","unstructured":"Graham NM, Hoover DR, Park LP, Stein DS, Phair JP, Mellors JW, Detels R, Saah AJ (1996) Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS cohort study group. Ann Intern Med 124:1031\u20131038","journal-title":"Ann Intern Med"},{"issue":"27","key":"440_CR48","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL et al (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363(27):2587\u20132599. doi:10.1056\/NEJMoa1011205","journal-title":"N Engl J Med"},{"issue":"1","key":"440_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/QAI.0b013e31828ece33","volume":"64","author":"LA Grohskopf","year":"2013","unstructured":"Grohskopf LA, Chillag KL, Gvetadze R et al (2013) Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquired Immune Defic Syndr 64(1):79\u201386","journal-title":"J Acquired Immune Defic Syndr"},{"issue":"11","key":"440_CR50","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJM199709113371102","volume":"337","author":"RM Gulick","year":"1997","unstructured":"Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337(11):734\u2013739","journal-title":"N Engl J Med"},{"issue":"1","key":"440_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/COH.0b013e32835b7f94","volume":"8","author":"RL Hamers","year":"2013","unstructured":"Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF (2013) Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 8(1):19\u201326","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"440_CR52","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/infdis\/jit086","volume":"207","author":"TJ Henrich","year":"2013","unstructured":"Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM et al (2013) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 207(11):1694\u20131702","journal-title":"J Infect Dis"},{"issue":"5","key":"440_CR53","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/M14-1027","volume":"161","author":"TJ Henrich","year":"2014","unstructured":"Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR (2014) Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161(5):319\u2013327. doi:10.7326\/M14-1027 (PubMed PMID: 25047577; PubMed Central PMCID: PMC4236912)","journal-title":"Ann Intern Med"},{"issue":"9","key":"440_CR54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/00002030-200006160-00018","volume":"14","author":"K Hertogs","year":"2000","unstructured":"Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA (2000) Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14(9):1203\u20131210","journal-title":"AIDS"},{"key":"440_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/373123a0","volume":"373","author":"DD Ho","year":"1995","unstructured":"Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123\u2013126","journal-title":"Nature"},{"key":"440_CR56","doi-asserted-by":"crossref","unstructured":"Hunt GM, Morris L, Moorthy A, Coovadia A, Abrams EJ, Strehlau R, Kuhn L, Persaud D (2014) Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods 207:182\u2013187 (PMC4150030)","DOI":"10.1016\/j.jviromet.2014.07.010"},{"issue":"7","key":"440_CR57","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K et al (2009) Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med 360(7):692\u2013698","journal-title":"N Engl J Med"},{"key":"440_CR58","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/jvi.70.2.1086-1090.1996","volume":"70","author":"AK Iversen","year":"1996","unstructured":"Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC (1996) Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70:1086\u20131090","journal-title":"J Virol"},{"key":"440_CR59","doi-asserted-by":"publisher","unstructured":"Jessen H, Allen TM, STreek H (2014) How a single patient influenced HIV research\u201415-year follow-up. N Engl J Med 370:682\u2013683. doi:10.1056\/NEJMc1308413","DOI":"10.1056\/NEJMc1308413"},{"issue":"3","key":"440_CR60","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.2649","volume":"18","author":"BL Jilek","year":"2012","unstructured":"Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, Shen L, Siliciano RF (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 18(3):446\u2013451. doi:10.1038\/nm.2649 (PubMed PMID: 22344296; PubMed Central PMCID: PMC3296892)","journal-title":"Nat Med"},{"issue":"3","key":"440_CR61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.idc.2014.06.003","volume":"28","author":"JA Johnson","year":"2014","unstructured":"Johnson JA, Sax PE (2014) Beginning antiretroviral therapy for patients with HIV. Infect Dis Clin North Am 28(3):421\u2013438","journal-title":"Infect Dis Clin North Am"},{"issue":"18","key":"440_CR62","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","volume":"16","author":"V Joly","year":"2002","unstructured":"Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, Yeni P (2002) Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16(18):2447\u20132454","journal-title":"AIDS"},{"key":"440_CR63","doi-asserted-by":"crossref","unstructured":"Kim RB (2003) Drug transporters in HIV Therapy. Top HIV Med 11(4):136\u2013139","DOI":"10.1046\/j.1468-1293.2003.00142.x"},{"issue":"17","key":"440_CR64","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1001\/archinte.158.17.1953","volume":"158","author":"H Knobel","year":"1998","unstructured":"Knobel H, Carmona A, Grau S, Pedro-Botet J, Diez A (1998) Adherence and effectiveness of highly active antiretroviral therapy. Arch Intern Med 158(17):1953","journal-title":"Arch Intern Med"},{"key":"440_CR65","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1126\/science.1377403","volume":"256","author":"LA Kohlstaedt","year":"1992","unstructured":"Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz RA (1992) Crystal structure at 3.5 a resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783\u20131790","journal-title":"Science"},{"key":"440_CR66","doi-asserted-by":"publisher","unstructured":"Kretzschmar ME, Schim van der Loeff MF, Birrell PJ, De Angelis D, Coutinho RA (2013) Prospects of elimination of HIV with test-and-treat strategy. Proc Natl Acad Sci USA 110(39):15538\u201315543. doi:10.1073\/pnas.1301801110 (Epub 2013 Sep PubMed PMID: 24009342; PubMed Central PMCID: PMC3785722)","DOI":"10.1073\/pnas.1301801110"},{"key":"440_CR67","doi-asserted-by":"publisher","unstructured":"Kulkarni SP, Shah KR, Sarma KV, Mahajan AP (2013) Clinical uncertainties, health service challenges, and ethical complexities of HIV \u201ctest-and-treat\u201d: a systematic review. Am J Public Health. 103(6):e14\u2013e23. doi:10.2105\/AJPH.2013.301273 (Epub 2013 Apr 18. Review. PubMed PMID: 23597344)","DOI":"10.2105\/AJPH.2013.301273"},{"issue":"10","key":"440_CR68","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"LH Kuller","year":"2008","unstructured":"Kuller LH, Tracy R, Belloso W et al (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5(10):e203","journal-title":"PLoS Med"},{"issue":"22","key":"440_CR69","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari JP, Henry KO, Hearn M et al (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348(22):2175\u20132185","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"440_CR70","first-page":"49","volume":"5","author":"BA Larder","year":"2000","unstructured":"Larder BA, Kemp SD, Hertogs K (2000) Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antiviral Ther 5(suppl 3):49","journal-title":"Antiviral Ther"},{"issue":"11","key":"440_CR71","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nrmicro3351","volume":"12","author":"SB Laskey","year":"2014","unstructured":"Laskey SB, Siliciano RF (2014) A mechanistic theory to explain the efficacy of antiretroviral therapy. Nat Rev Microbiol 12(11):772\u2013780. doi:10.1038\/nrmicro3351 (Epub 2014 Sep 29)","journal-title":"Nat Rev Microbiol"},{"issue":"22","key":"440_CR72","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1056\/NEJMoa035211","volume":"348","author":"A Lazzarin","year":"2003","unstructured":"Lazzarin A, Clotet B, Cooper D et al (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348(22):2186\u20132195","journal-title":"N Engl J Med"},{"key":"440_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0166-3542(00)00102-9","volume":"47","author":"JM Lenhard","year":"2000","unstructured":"Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA, Weiel JE (2000) HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 47:121\u2013129","journal-title":"Antiviral Res"},{"issue":"6","key":"440_CR74","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJMoa013552","volume":"347","author":"SJ Little","year":"2002","unstructured":"Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347(6):385\u2013394","journal-title":"N Engl J Med"},{"key":"440_CR75","doi-asserted-by":"crossref","unstructured":"Loutfy MR, Antoniou T, Shen S, Diong C, Vlaicu M, Halpenny R, Kovacs C, Fletcher D, Raboud JM (2007) Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. HIV Clin Trials 8(1):36\u201344 (PMID: 17434847)","DOI":"10.1310\/hct0801-36"},{"key":"440_CR76","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727\u2013732","journal-title":"Lancet"},{"issue":"7","key":"440_CR77","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","volume":"17","author":"PW Mallon","year":"2003","unstructured":"Mallon PW, Miller J, Cooper DA, Carr A (2003) Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17(7):971\u2013979","journal-title":"AIDS"},{"key":"440_CR78","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0006-2952(00)00408-1","volume":"60","author":"C Mao","year":"2000","unstructured":"Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM (2000) Structure-based drug design of non-nucleoside inhibitors for wild-type and drug resistant HIV reverse transcriptase. Biochem Pharmacol 60:1251\u20131265","journal-title":"Biochem Pharmacol"},{"key":"440_CR500","doi-asserted-by":"crossref","unstructured":"Mathias AA, German P, Murray BP, Jain A, West S, Warren D, Hui J, Kearney BP (2010) Pharmacokinetics and pharmacodynamics of GS-9530: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmaco Ther 87:322\u2013329","DOI":"10.1038\/clpt.2009.228"},{"issue":"12","key":"440_CR79","doi-asserted-by":"publisher","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","volume":"126","author":"JW Mellors","year":"1997","unstructured":"Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126(12):946\u2013954","journal-title":"Ann Intern Med"},{"key":"440_CR80","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7326\/0003-4819-116-1-13","volume":"116","author":"TC Meng","year":"1992","unstructured":"Meng TC, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, Lai SH, Wright B, Richman DD (1992) Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I\/II study. Ann Intern Med 116:13\u201320","journal-title":"Ann Intern Med"},{"key":"440_CR81","doi-asserted-by":"crossref","unstructured":"Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Kr\u00f6hn A, Lambert RW, Merrett, MJS, Parkes KEB, Redshaw S, Ritchie AJ, Taylor DL, Thomas GJ, Machin PJ (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358","DOI":"10.1126\/science.2183354"},{"key":"440_CR82","doi-asserted-by":"crossref","unstructured":"Montaner JS, Harrigan PR, Jahnke N et al (2001) Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15(1):61\u201369","DOI":"10.1097\/00002030-200101050-00010"},{"key":"440_CR83","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/00002030-200103300-00011","volume":"15","author":"RD Moore","year":"2001","unstructured":"Moore RD, Keruly JC, Chaisson RE (2001) Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 15:617\u2013620","journal-title":"AIDS"},{"issue":"Suppl 1","key":"440_CR84","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1093\/cid\/ciu299","volume":"59","author":"JB Nachega","year":"2014","unstructured":"Nachega JB, Uthman OA, del Rio C, Mugavero MJ, Rees H, Mills EJ (2014) Addressing the Achilles\u2019 heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis 59(Suppl 1):S21\u2013S27. doi:10.1093\/cid\/ciu299 PubMed PMID: 24926028; PubMed Central PMCID:PMC4141496","journal-title":"Clin Infect Dis"},{"key":"440_CR85","doi-asserted-by":"crossref","unstructured":"Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, Mellors J, Morris L, Coffin J (2006) Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 103(18):7094\u20137099 (PMCID: PMC1459023)","DOI":"10.1073\/pnas.0602033103"},{"key":"440_CR86","doi-asserted-by":"crossref","unstructured":"Paredes R, Marconi VC, Campbell TB, Kuritzkes DR (2007) Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 146(1\u20132):136\u201346 (PMCID: PMC4195598)","DOI":"10.1016\/j.jviromet.2007.06.012"},{"issue":"1","key":"440_CR87","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"DL Paterson","year":"2000","unstructured":"Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133(1):21\u201330","journal-title":"Ann Intern Med"},{"key":"440_CR88","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","volume":"271","author":"AS Perelson","year":"1996","unstructured":"Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582\u20131586","journal-title":"Science"},{"key":"440_CR89","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","volume":"369","author":"D Persaud","year":"2013","unstructured":"Persaud D, Gay H, Ziemniak C et al (2013) Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 369:1828\u20131835","journal-title":"N Engl J Med"},{"issue":"5","key":"440_CR90","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1371\/journal.pctr.0020027","volume":"2","author":"L Peterson","year":"2007","unstructured":"Peterson L, Taylor D, Roddy R et al (2007) Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2(5):e27","journal-title":"PLoS Clin Trials"},{"key":"440_CR91","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","volume":"20","author":"RB Pollard","year":"1998","unstructured":"Pollard RB, Robinson P, Dransfield K (1998) Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 20:1071\u20131089","journal-title":"Clin Ther"},{"issue":"1","key":"440_CR92","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/QAD.0b013e32833032ed","volume":"24","author":"AL Pozniak","year":"2010","unstructured":"Pozniak AL, Morales-Ramirez J, Katabira E et al (2010) TMC278-C204 study group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 24(1):55\u2013565","journal-title":"AIDS"},{"issue":"17","key":"440_CR93","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","volume":"13","author":"JM Prins","year":"1999","unstructured":"Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, ten Berge IJ, Yong SL, Fox CH, Roos MT, de Wolf F, Goudsmit J, Schuitemaker H, Lange JM (1999) Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13(17):2405\u20132410","journal-title":"AIDS"},{"issue":"1","key":"440_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/COH.0000000000000127","volume":"10","author":"K Rainwater-Lovett","year":"2015","unstructured":"Rainwater-Lovett K, Luzuriaga K, Persaud D (2015) Very early combination antiretroviral therapy in infants: prospects for cure. Curr Opin HIV AIDS 10(1):4\u201311. doi:10.1097\/COH.0000000000000127","journal-title":"Curr Opin HIV AIDS"},{"key":"440_CR95","doi-asserted-by":"publisher","unstructured":"Rasmussen TA, Tolstrup M, Winckelmann A, \u00d8stergaard L, S\u00f8gaard OS (2013) Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 9(4):790\u2013799. doi:10.4161\/hv.23202 (Epub 2013 Apr 1. Review. PMCID: PMC3903897)","DOI":"10.4161\/hv.23202"},{"key":"440_CR96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/135965350000500110","volume":"5","author":"D Richman","year":"2000","unstructured":"Richman D (2000) Principles of HIV resistance testing and overview of assay performance characteristics. Antivir Ther 5:27\u201331","journal-title":"Antivir Ther"},{"issue":"1","key":"440_CR97","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","volume":"59","author":"L Rimsky","year":"2012","unstructured":"Rimsky L, Vingerhoets J, Van Eygen V et al (2012) Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 59(1):39\u2013346","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"Suppl 1","key":"440_CR98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/liv.12721","volume":"35","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK (2015) Optimal therapy of HIV\/HCV co-infected patients with direct acting antivirals. Liver Int 35(Suppl 1):51\u2013555. doi:10.1111\/liv.12721","journal-title":"Liver Int"},{"issue":"6","key":"440_CR99","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nm0696-625","volume":"2","author":"MS Saag","year":"1996","unstructured":"Saag MS, Holodniy M, Kuritzkes DR, O\u2019Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA (1996) HIV viral load markers in clinical practice. Nat Med 2(6):625\u2013629","journal-title":"Nat Med"},{"issue":"9622","key":"440_CR100","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"CA Sabin","year":"2008","unstructured":"Sabin CA, Worm SW, Weber R et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A: D study: a multi-cohort collaboration. Lancet 371(9622):1417\u20131426","journal-title":"Lancet"},{"key":"440_CR101","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Ciri\u00f3n A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 9(3):e1003211 (PMC3597518 ANRS) (VISCONTI study group)","DOI":"10.1371\/journal.ppat.1003211"},{"issue":"6","key":"440_CR102","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiq118","volume":"203","author":"NG Sandler","year":"2011","unstructured":"Sandler NG, Wand H, Roque A et al (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. JInfect Dis 203(6):780\u2013790","journal-title":"JInfect Dis"},{"key":"440_CR103","doi-asserted-by":"crossref","unstructured":"Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF (1996) Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis 173:1354\u20131366","DOI":"10.1093\/infdis\/173.6.1354"},{"issue":"1","key":"440_CR104","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00126334-200009010-00003","volume":"25","author":"AN Scribner","year":"2000","unstructured":"Scribner AN, Troia-Cancio PV, Cox BA, Marcantonio D, Hamid F, Keiser P, Levi M, Allen B, Murphy K, Jones RE, Skiest DJ (2000) Osteonecrosis in HIV: a case-control study. J Acquir Immune Defic Syndr 25(1):19\u201325","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"440_CR105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/135965350200700306","volume":"7","author":"E Seminari","year":"2002","unstructured":"Seminari E, Tinelli C, Minoli L, Sacchi P, Filice G, Zocchetti C, Meneghetti G, Bruno R, Maserati R (2002) Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther 7(3):175\u2013180","journal-title":"Antivir Ther"},{"key":"440_CR106","doi-asserted-by":"crossref","unstructured":"Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15:247\u2013277","DOI":"10.1128\/CMR.15.2.247-277.2002"},{"key":"440_CR107","doi-asserted-by":"publisher","unstructured":"Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF (2011) A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci Trans Med 3(91):91ra63. doi:10.1126\/scitranslmed.3002304 (PubMed PMID: 21753122; PubMed Central PMCID: PMC3488347)","DOI":"10.1126\/scitranslmed.3002304"},{"issue":"9","key":"440_CR108","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jnci\/djr076","volume":"103","author":"MS Shiels","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Gail MH et al (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753\u2013762","journal-title":"J Natl Cancer Inst"},{"key":"440_CR109","doi-asserted-by":"crossref","unstructured":"Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, Gabriel C, Izopet J, Kessler HH, Stelzl E, Di Giallonardo F, Schlapbach R, Radonic A, Paredes R, Recordon-Pinson P, Sakwa J, St John EP, Schmitz-Agheguian GG, Metzner KJ, D\u00e4umer MP (2014) 454 HIV Alphastudy Group. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. J Virol Methods 204:31\u201337 (PMID: 24731928)","DOI":"10.1016\/j.jviromet.2014.04.007"},{"key":"440_CR110","doi-asserted-by":"crossref","unstructured":"Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM et al (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci 91:3911\u20133915","DOI":"10.1073\/pnas.91.9.3911"},{"issue":"10","key":"440_CR111","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","volume":"24","author":"C Smith","year":"2010","unstructured":"Smith C (2010) Factors associated with specific causes of death amongst HIV-positive individuals in the D:A: D study. AIDS 24(10):1537\u20131548","journal-title":"AIDS"},{"key":"440_CR112","doi-asserted-by":"crossref","unstructured":"St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ et al (1987) 3\u2032-Azido-3\u2032-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31:1972\u20131977","DOI":"10.1128\/AAC.31.12.1972"},{"issue":"8","key":"440_CR113","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1073\/pnas.0736332100","volume":"100","author":"MC Strain","year":"2003","unstructured":"Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 100(8):4819\u20134824","journal-title":"Proc Natl Acad Sci USA"},{"key":"440_CR114","doi-asserted-by":"crossref","unstructured":"Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, Spina CA, Woelk CH, Richman DD (2013) Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 8(4):e55943 (PMCID: PMC3616050)","DOI":"10.1371\/journal.pone.0055943"},{"key":"440_CR115","doi-asserted-by":"crossref","unstructured":"Tang MW, Shafer RW (2012) HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 72(9):e1\u2013e25 (PMCID: PMC3689909)","DOI":"10.2165\/11633630-000000000-00000"},{"issue":"5","key":"440_CR116","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA et al (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367(5):423\u2013434","journal-title":"N Engl J Med"},{"key":"440_CR117","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1073\/pnas.63.3.871","volume":"63","author":"L Toji","year":"1969","unstructured":"Toji L, Cohen S (1969) The enzymatic termination of polydeoxynucleotides by 2\u2032,3\u2032-dideoxydenosine triphosphate. Proc Natl Acad Sci 63:871\u2013877","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"440_CR118","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00002030-200201250-00010","volume":"16","author":"C Tural","year":"2002","unstructured":"Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B (2002) Havana study group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16(2):209\u2013218","journal-title":"AIDS"},{"key":"440_CR119","unstructured":"United States Food and Drug Administration (2014) Antiretroviral drugs used in the treatment of HIV infection. Sept 2014. http:\/\/www.fda.gov\/ForPatients\/Illness\/HIVAIDS\/Treatment\/ucm118915.htm"},{"key":"440_CR120","unstructured":"US Public Health Service (2014) Preexposure prophylaxis for the prevention of HIV infection in the united states\u20142014 clinical practice guideline. Centers for disease control, URL\u2014http:\/\/www.cdc.gov\/hiv\/pdf\/PrEPguidelines2014.pdf"},{"key":"440_CR121","doi-asserted-by":"crossref","unstructured":"Valencia ME, Barreiro P, Soriano V, Blanco F, Moreno V, Lahoz JG (2003) Avascular necrosis in HIV-infected patients receiving antiretroviral treatment: study of seven cases. HIV Clin Trials 4(2):132\u2013136","DOI":"10.1310\/8EW3-GYJ9-08NA-6D5H"},{"issue":"5","key":"440_CR122","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K et al (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367(5):411\u2013422","journal-title":"N Engl J Med"},{"key":"440_CR123","doi-asserted-by":"crossref","unstructured":"Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10(4):e1004071 (PMCID: PMC3983056)","DOI":"10.1371\/journal.ppat.1004071"},{"key":"440_CR124","unstructured":"Wensing AM, Calvez V, G\u00fcnthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD (2014) 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 22(3):642\u2013650 (PubMed PMID: 25101529)"},{"key":"440_CR125","unstructured":"World Health Organization (2014) Global update on the health sector response to HIV. HIV reporting. ISBN 9789241507585"},{"issue":"4","key":"440_CR126","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1468-1293.2002.00125.x","volume":"3","author":"D Worm","year":"2002","unstructured":"Worm D, Kirk O, Andersen O, Vinten J, Gerstoft J, Katzenstein TL, Nielsen H, Pedersen CR (2002) Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. HIV Med 3(4):239\u2013246","journal-title":"HIV Med"},{"key":"440_CR127","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/1471-2334-13-471","volume":"13","author":"SW Worm","year":"2013","unstructured":"Worm SW, Bower M, Reiss P et al (2013) Non-AIDS defining cancers in the D:A: D study\u2013time trends and predictors of survival: a cohort study. BMC Infect Dis 13:471","journal-title":"BMC Infect Dis"},{"key":"440_CR128","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJM198702263160925","volume":"316","author":"R Yatchoan","year":"1987","unstructured":"Yatchoan R, Broder S (1987) Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders; a progress report. N Engl J Med 316:557\u2013564","journal-title":"N Engl J Med"},{"key":"440_CR129","doi-asserted-by":"crossref","unstructured":"Youle M, Tyrer M, Fisher M et al (2002) Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J Acquir Immun Defic Syndr 29(1):58\u201361","DOI":"10.1097\/00042560-200201010-00008"},{"issue":"5","key":"440_CR130","doi-asserted-by":"publisher","first-page":"e1003347","DOI":"10.1371\/journal.ppat.1003347","volume":"9","author":"SA Yukl","year":"2013","unstructured":"Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D et al (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 9(5):e1003347","journal-title":"PLoS Pathog"}],"container-title":["Current Topics in Microbiology and Immunology","The Future of HIV-1 Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2015_440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:44:42Z","timestamp":1676432682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2015_440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319185170","9783319185187"],"references-count":130,"URL":"https:\/\/doi.org\/10.1007\/82_2015_440","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"29 March 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}